GT Biopharma, Inc.

GT Biopharma, Inc., trading as GTBP, is advancing targeted immunotherapies rooted in its proprietary TriKE and antibody-cytokine fusion platforms, supplying biopharma partners, academic medical centers, and specialty oncology practices with clinical-stage candidates focused on hematologic malignancies and solid tumors under the Pharmaceutical Preparations (SIC 2834) umbrella. CIK 109657 maps the company’s regulatory trajectory, as evidenced by the Form 8-K filed in November 2025 outlining corporate governance changes and development updates that ripple through capital planning. Beyond molecule design, the firm supplements its pipeline with translational development services and compliance consulting so collaborators can navigate reimbursement pathways, and it relies on contract research organizations and specialized trial sites to accelerate IND-enabling studies while equipping hospitals and community oncology networks to enroll patients. Its outlook hinges on managing material risks such as regulatory approvals, clinical-stage data, manufacturing scale, and supply-chain controls while abiding by FDA, SEC, and international guidelines. Stay aware and view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025